Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1451 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Cmax of ABBV-1451.
Tmax of ABBV-1451.
β of ABBV-1451.
t1/2 of ABBV-1451.
AUCt of ABBV-1451.
AUCinf of ABBV-1451.
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 5 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 6 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo. |
| Part 2: Group 7 | EXPERIMENTAL | Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Part 2: Group 8 | EXPERIMENTAL | Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-1451 | DRUG | Injection |
| Placebo | OTHER | Injection |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. * Applies to Part 2 only: * For Japanese participants: \-- Participant must be first or second-generation Japanese of fu...
ABBV-1451 is an investigational small molecule being developed by AbbVie Inc. (ticker: ABBV). It is in Phase 1 clinical development and is being evaluated in a single ascending dose study in healthy adult participants. The specific therapeutic indication for ABBV-1451 has not been disclosed.
ABBV-1451 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the Phase 1 clinical trial evaluating the compound.
ABBV-1451 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The single active trial is a Phase 1 study, and no completed trials have been reported for this asset.
ABBV-1451 is being studied in one active Phase 1 trial, NCT07570147, titled a study to evaluate the pharmacokinetics, safety, and tolerability of single ascending doses of ABBV-1451 infusions and injections in healthy adult participants. The trial is recruiting, is randomized and double-blind, and has an estimated enrollment of 90 participants in the United States.
The ABBV-1451 Phase 1 trial, NCT07570147, is a randomized, double-blind, controlled study of single ascending doses given as infusions and injections. It enrolls healthy adult volunteers aged 18 years and older of all sexes, with an estimated enrollment of 90 participants across sites in the United States.